keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic borderline

keyword
https://www.readbyqxmd.com/read/29777302/emerging-strategies-in-brca-positive-pancreatic-cancer
#1
REVIEW
Adam Kowalewski, Łukasz Szylberg, Michał Saganek, Wojciech Napiontek, Paulina Antosik, Dariusz Grzanka
PURPOSE: We propose a treatment algorithm for PDAC with particular emphasis on BRCA1 or 2 mutation-positive patients. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest diseases in the United States and Europe. BRCA1 and BRCA2 are among the most common of the known genetic mutations involved in familial PDAC. The optimal chemotherapy regimen to use for BRCA1 or 2 mutation carriers with PDAC is not yet established. As new treatment options emerge, algorithms must balance the need to give the best drugs first with ensuring that there are still beneficial options available for later...
May 18, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29773761/surgical-treatment-of-pancreatic-cancer
#2
Wioletta Masiak-Segit, Karol Rawicz-Pruszyński, Magdalena Skórzewska, Wojciech P Polkowski
The only way to cure the patient with adenocarcinoma of the pancreas (RT) is surgical excision of the tumor. The standard surgical treatment of resectable pancreatic carcinoma is considered the classic pancreatoduodenectomy (PD) with the Kausch- Whipple procedure, or the pylorus-preserving PD with the Traverso-Longmire method. The most difficult technically and at the same time the most important PD stage from an oncological point of view is the separation of the head of the pancreas from the superior mesenteric artery...
April 30, 2018: Polski Przeglad Chirurgiczny
https://www.readbyqxmd.com/read/29761331/folfirinox-versus-gemcitabine-nab-paclitaxel-for-neoadjuvant-treatment-of-resectable-and-borderline-resectable-pancreatic-head-adenocarcinoma
#3
Mashaal Dhir, Mazen S Zenati, Ahmad Hamad, Aatur D Singhi, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, Amer H Zureikat
BACKGROUND: Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA). This study aimed to compare neoadjuvant FOLFIRINOX and G-nP in the treatment of resectable (R) and borderline resectable (BR) head PDA. METHODS: A single-institution retrospective review of R and BR patients undergoing pancreaticoduodenectomy after NAT with FOLFIRINOX or G-nP was performed. Comparative analysis was performed using inverse-probability-weighted (IPW) estimators...
May 14, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29722658/management-of-borderline-resectable-pancreatic-cancer
#4
REVIEW
Diego A S Toesca, Amanda J Koong, George A Poultsides, Brendan C Visser, Sigurdis Haraldsdottir, Albert C Koong, Daniel T Chang
With the rapid development of imaging modalities and surgical techniques, the clinical entity representing tumors that are intermediate between resectable and unresectable pancreatic adenocarcinoma has been identified has been termed "borderline resectable" (BR). These tumors are generally amenable for resection but portend an increased risk for positive margins after surgery and commonly necessitate vascular resection and reconstruction. Although there is a lack of consensus regarding the appropriate definition of what constitutes a BR pancreatic tumor, it has been demonstrated that this intermediate category carries a particular prognosis that is in between resectable and unresectable disease...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29718872/anatomical-segmentectomy-of-the-pancreatic-head-along-the-embryological-fusion-plane-a-case-series-and-a-literature-review
#5
Chunfu Zhu, Zhongzhi Jia, Xudong Zhang, Qiang Yu, Xihu Qin
RATIONALE: Anatomical segmentectomy of the pancreatic head along the embryological fusion plane (EFP) has been used in the treatment of benign, borderline, and low-grade malignancy neoplasms. However, few studies have reported on the outcomes of this procedure. The aim of this study was to retrospectively assess the outcomes of anatomical segmentectomy of the pancreatic head along the EFP. PATIENT CONCERNS: We experienced two patients who underwent anatomical segmentectomy of the pancreatic head along the EFP for the treatment of pancreatic cystadenoma...
May 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29717230/therapeutic-developments-in-pancreatic-cancer-current-and-future-perspectives
#6
REVIEW
John P Neoptolemos, Jörg Kleeff, Patrick Michl, Eithne Costello, William Greenhalf, Daniel H Palmer
The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the next decade in Western countries. The past few years, however, have seen improvements in first-line and second-line palliative therapies and considerable progress in increasing survival with adjuvant treatment. The use of biomarkers to help define treatment and the potential of neoadjuvant therapies also offer opportunities to improve outcomes...
May 1, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29708592/meta-analysis-comparing-upfront-surgery-with-neoadjuvant-treatment-in-patients-with-resectable-or-borderline-resectable-pancreatic-cancer
#7
REVIEW
E Versteijne, J A Vogel, M G Besselink, O R C Busch, J W Wilmink, J G Daams, C H J van Eijck, B Groot Koerkamp, C R N Rasch, G van Tienhoven
BACKGROUND: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer. METHODS: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment...
April 30, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29679211/surgery-after-folfirinox-treatment-for-locally-advanced-and-borderline-resectable-pancreatic-cancer-increase-in-tumour-attenuation-on-ct-correlates-with-r0-resection
#8
Giovanni Marchegiani, Valentina Todaro, Enrico Boninsegna, Riccardo Negrelli, Binit Sureka, Debora Bonamini, Roberto Salvia, Riccardo Manfredi, Roberto Pozzi Mucelli, Claudio Bassi
OBJECTIVES: To assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX. METHODS: Patients with either locally advanced (LA) and borderline resectable (BR) PDAC undergoing surgical exploration after FOLFIRINOX were retrospectively enrolled. Two pancreatic radiologists reviewed the CT blinded to the final outcome and assessed chemotherapy response and resectability. Patients were then divided into R0 resected (group A) and not resected/R1 resected (group B), which were compared...
April 20, 2018: European Radiology
https://www.readbyqxmd.com/read/29672417/preoperative-chemoradiation-for-borderline-resectable-pancreatic-cancer-the-new-standard
#9
Matthew Hg Katz, Michael P Kim, Ching-Wei Tzeng, Jeffrey E Lee
No abstract text is available yet for this article.
April 18, 2018: Annals of Surgery
https://www.readbyqxmd.com/read/29668371/comparison-of-metal-and-plastic-stents-for-preoperative-biliary-drainage-in-resectable-and-borderline-resectable-periampullary-cancer-a-meta-analysis-and-system-review
#10
Pan Liu, Huapeng Lin, Yuanyuan Chen, Yu-Shen Wu, Maocai Tang, Changan Liu
AIM: The aim of this study was to compare the plastic stents with metal stents for preoperative biliary drainage (PBD) in terms of the rate of endoscopic reintervention and PBD-related pre- and postoperative complications in patients with resectable and borderline resectable periampullary cancer. METHODS: We conducted a comprehensive search of the PubMed, EMBASE, and the Cochrane Library database to identify relevant available articles from their inception to September 2017...
April 18, 2018: Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A
https://www.readbyqxmd.com/read/29649825/the-role-of-staging-laparoscopy-in-resectable-and-borderline-resectable-pancreatic-cancer-a-systematic-review-and-meta-analysis
#11
Robert Ta, Donal B O'Connor, Andrew Sulistijo, Benjamin Chung, Kevin C Conlon
AIM: The study aimed to determine the additional value of staging laparoscopy in patients with pancreatic cancer deemed potentially resectable based on computed tomography imaging. METHODS: A systematic literature search was performed using MEDLINE and the Cochrane Register of Controlled Trials (January 1995 to June 2017). Primary outcome measures were the overall yield and sensitivity to detect non-resectable disease. Quality of studies was assessed with the Newcastle-Ottawa Scale...
April 12, 2018: Digestive Surgery
https://www.readbyqxmd.com/read/29629335/intraoperative-radiation-boost-to-the-surgical-resection-bed-following-pancreaticoduodenectomy-for-a-borderline-resectable-pancreatic-carcinoma-a-case-report
#12
Tarita O Thomas, William Small, Mark Fleming, Song Kang, Richard A Hoefer
Neoadjuvant therapy including chemotherapy alone or concurrent chemotherapy with external bream radiation is a standard treatment strategy for borderline resectable pancreatic adenocarcinoma and is also used routinely for primary operable cancers at some institutions (1). The use of intraoperative radiation therapy (IORT) has been limited largely because of the logistical issues in delivery of radiation during surgery (2). This is the first reported case of a borderline resectable pancreas cancer patient who underwent neoadjuvant chemo-radiation therapy followed by resection with the use of IORT using the mobile IntraBeam device to boost the resection bed and improve local control by dose escalation...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29602996/laparoscopic-pancreaticoduodenectomy-with-major-venous-resection-and-reconstruction-anterior-superior-mesenteric-artery-first-approach
#13
Yunqiang Cai, Pan Gao, Yongbin Li, Xin Wang, Bing Peng
BACKGROUND: The en bloc resection of the superior mesenteric or portal vein with concomitant venous reconstruction may be required in patients with borderline resectable pancreatic cancer. However, performing laparoscopic pancreaticoduodenectomy (LPD) with major venous resection and reconstruction is technically challenging. Herein, we introduced a safe and feasible technique to perform LPD with major venous resection. METHODS: Over the period of November 2015 to November 2016, 18 patients underwent laparoscopic pancreaticoduodenectomy with major venous resection and reconstruction using the anterior superior mesenteric artery (SMA)-first approach at our institution...
March 30, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29590448/18f-fluorodeoxyglucose-positron-emission-tomography-to-indicate-conversion-surgery-in-patients-with-initially-unresectable-locally-advanced-pancreatic-cancer
#14
Keiichi Okano, Hironobu Suto, Minoru Oshima, Yasuhisa Ando, Mina Nagao, Hideki Kamada, Hideki Kobara, Tsutomu Masaki, Hiroyuki Okuyama, Yoshihiro Okita, Akihito Tsuji, Yasuyuki Suzuki
Objective: Advances in chemotherapy and chemoradiotherapy have enabled conversion of initially unresectable locally advanced (UR-LA) pancreatic adenocarcinoma (PDAC) to a resectable disease. However, definitive criteria for conversion surgery have not been established. We evaluated the potential of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to indicate conversion surgery in patients with primary UR-LA PDAC. Methods: Twenty consecutive patients with UR-LA PDAC underwent chemoradiation or chemotherapy followed by assessment with FDG-PET...
March 26, 2018: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29564168/impact-of-sarcopenia-in-borderline-resectable-and-locally-advanced-pancreatic-cancer-patients-receiving-stereotactic-body-radiation-therapy
#15
William H Jin, Eric A Mellon, Jessica M Frakes, Gilbert Z Murimwa, Pamela J Hodul, Jose M Pimiento, Mokenge P Malafa, Sarah E Hoffe
Background: Total psoas area (TPA), a marker of sarcopenia, has been used as an independent predictor of clinical outcomes in gastrointestinal (GI) cancers as a proxy for frailty and nutritional status. Our study aimed to evaluate whether TPA, in contrast to traditional measurements of nutrition like body mass index (BMI) and body surface area (BSA), was predictive of outcomes in borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) patients receiving stereotactic body radiation therapy (SBRT)...
February 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29553402/neoadjuvant-phase-ii-trial-of-chemo-radiotherapy-crt-in-patients-with-resectable-r-and-borderline-resectable-br-pancreatic-ductal-adenocarcinoma-pda
#16
V Damarla, D Dobrosotskaya, F Siddiqui, I Wollner, M Raoufi, J Li, D Kwon, G Khan
No abstract text is available yet for this article.
March 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29510561/survival-analysis-in-patients-with-pancreatic-ductal-adenocarcinoma-undergoing-chemoradiotherapy-followed-by-surgery-according-to-the-international-consensus-on-the-2017-definition-of-borderline-resectable-cancer
#17
Aoi Hayasaki, Shuji Isaji, Masashi Kishiwada, Takehiro Fujii, Yusuke Iizawa, Hiroyuki Kato, Akihiro Tanemura, Yasuhiro Murata, Yoshinori Azumi, Naohisa Kuriyama, Shugo Mizuno, Masanobu Usui, Hiroyuki Sakurai
Background : The aim of this study was to validate a new definition of borderline resectable pancreatic ductal adenocarcinoma (PDAC) provided by the 2017 international consensus on the basis of three dimensions of anatomical (A), biological (B), and conditional (C) factors, using the data of the patients who had been registered for our institutional protocol of chemoradiotherapy followed by surgery (CRTS) for localized patients with PDAC. Methods : Among 307 consecutive patients pathologically diagnosed with localized PDAC who were enrolled in our CRTS protocol from February 2005 to December 2016, we selected 285 patients who could be re-evaluated after CRT...
March 5, 2018: Cancers
https://www.readbyqxmd.com/read/29491271/effects-of-pediococcus-acidilactici-r037-on-serum-triglyceride-levels-in-mice-and-rats-after-oral-administration
#18
Takahiro Ueda, Airo Tategaki, Kazuya Hamada, Hideyuki Kishida, Kazunori Hosoe, Hideyuki Morikawa, Kaku Nakagawa
The biological effects of heat-killed Pediococcus acidilactici R037 (R037) were evaluated when orally administered in mice and rats. Oral R037 administration at a daily dose of 10 and 100 mg/kg for 3 wk dose-dependently reduced fasting and non-fasting serum triglyceride concentrations in KK-Ay /TaJcl mice, a model of type II diabetes, obesity, hypercholesterolemia, and hypertriglyceridemia. Serum levels of free fatty acids in the 100 mg/kg group tended to decrease (not statistically significant), and total cholesterol levels remained unchanged...
2018: Journal of Nutritional Science and Vitaminology
https://www.readbyqxmd.com/read/29489408/preoperative-mdct-assessment-of-resectability-in-borderline-resectable-pancreatic-cancer-effect-of-neoadjuvant-chemoradiation-therapy
#19
Ijin Joo, Jeong Min Lee, Eun Sun Lee, Su Joa Ahn, Dong Ho Lee, Sun-Whe Kim, Ji Kon Ryu, Do-Youn Oh, Kyubo Kim, Kyoung-Bun Lee, Jin-Young Jang
OBJECTIVE: The purpose of this study is to evaluate the diagnostic performance of MDCT in assessing tumor resectability in patients with borderline resectable pancreatic cancers after receiving neoadjuvant chemoradiation therapy (CRT) in comparison with those undergoing upfront surgery. SUBJECTS AND METHODS: Thirty-seven patients with borderline resectable pancreatic cancers were randomly allocated to the neoadjuvant CRT group (arm 1; n = 18) or up-front surgery group (arm 2; n = 19)...
May 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29483443/-conversion-surgery-for-pancreatic-head-cancer-with-peritoneal-dissemination-following-chemotherapy-for-two-years-a-case-report
#20
Yuuri Hatsuzawa, Masamichi Mizuma, Fuyuhiko Motoi, Tatsuo Hata, Masahiro Iseki, Tatsuyuki Takadate, Hideo Ohtsuka, Naoaki Sakata, Takanori Morikawa, Kei Nakagawa, Hiroki Hayashi, Takeshi Naitoh, Atsushi Kanno, Tooru Shimosegawa, Michiaki Unno
Here we report a case of pancreatic cancer(PC)with peritoneal dissemination, underwent conversion surgery following chemotherapy for 2 years. A5 5-year-old woman was referred to our hospital for treatment of PC. Abdominal CT scan revealed 3.0 cm of a pancreatic head tumor with abutment of the portal vein and the hepatic artery, classified as borderline resectable. Staging laparoscopy(SL)showed positive peritoneal cytology(CY). Gemcitabine(Gem)plus S-1 therapy(GS) was performed. Ten months after initial GS, SL revealed the disseminated nodule and positive CY...
February 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
101386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"